When the Supreme Court overturned Roe v. Wade a key question was what the US Food and Drug Administration might do to ensure access to the medication abortion drug mifepristone. But the decision has had far greater repercussions, as organizations and states are now threatening the agency’s ability to approve and regulate drugs.
The most imminent concern is the forthcoming ruling in the Alliance for Hippocratic Medicine’s suit against the agency. The plaintiffs,...




